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Introduction 
Naltrexone is a competitive antagonist of μ, k, and γ 
opioid receptors, synthesized in 1963 and approved 
by FDA in 1984 for treatment of alcoholism and 
opioid addiction [1]. It is a fat-soluble substance 
absorbed from the gastrointestinal tract and bio-
transformed in the liver into 6-betanaltrexol, its 
active metabolite, which crosses the blood-brain 
barrier, promoting attenuation or complete and 
reversible blockade of the opioid effects. Naltrexone 
is rapidly distributed to tissues and has a plasma half-
life is of 13 hours. It has a slow terminal elimination-
phase half-life of 96 hours, predominantly involving 
urinary excretion [1-3]. It is routinely available in 
50mg tablets and can be administered by 
subcutaneous, intravenous, or intramuscular 
injections. In dermatological conditions, it has been 
used off-label in trichotillomania and refractory 
pruritus [1,2]. Recently, low-dose naltrexone (LDN), 
defined as up to 1/10 of the regular dose used for 
treatment of opioid dependence, has been reported 
to be helpful in a wide variety of diseases. The use of 
naltrexone at doses lower than 5mg daily has a 
paradoxical effect, leading to an increase in 
endogenous  
opioids, including beta-endorphins, which have anti-
inflammatory properties [2,3]. Low-dose naltrexone 
also plays a role in modulating the neuroimmune 
axis by its action on maturation of dendritic cells and 
in mitochondrial apoptosis. It inhibits proliferation of 
T and B lymphocytes and toll-like receptor 4 (TLR4) 
and reduces release of IL1, IL6, IL10, TNF, IFNβ, and 
nitric oxide. These mechanisms may also justify their 
possible role in the treatment of inflammatory 
conditions [3]. Therefore, it has become a potential 
adjuvant therapy in multiple sclerosis, fibromyalgia, 
Crohn disease, and Hailey-Hailey disease [1,2]. The 
Abstract 
Naltrexone is a competitive antagonist of μ, k and γ 
opioid receptors, used for treatment of alcoholism 
and opioid addiction. Low-dose naltrexone (LDN) is 
defined as daily doses ranging from 1mg to 5mg. 
This is purported to have a paradoxical effect that 
leads to an increase in endogenous opioids, 
including beta-endorphins, which have anti-
inflammatory properties. Theses mechanisms may 
also justify their possible role in the treatment of 
inflammatory conditions. The aim of this article is to 
discuss the use of LDN as an adjuvant therapeutic 
option in symptomatic alopecias presenting with 
trichodynia. Trichodynia is defined as scalp 
discomfort of variable intensity presenting as diffuse 
or localized dysesthesia and may be described by 
patients as pain, pruritus, or burning. These are 
common symptoms in patients with hair loss that 
negatively impacts quality of life. Scalp discomfort 
may be refractory to conventional therapies and 
does not yet have a specific therapeutic guideline. 
For these cases, LDN would be a possible alternative 
to be added to the therapeutic arsenal owing to its 
anti-inflammatory properties, analgesic potential, 
low cost, and few adverse effects described. Further 
studies are needed to standardize dosing, better 
understand its mechanism of action, and evaluate its 
potential therapeutic indications. 
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aim of this article is to discuss the use of LDN as an 
adjuvant therapeutic option in symptomatic 
alopecias presenting with trichodynia. 
 
Discussion 
Trichodynia is defined as scalp discomfort of variable 
intensity. It seems to be related to release of 
substance P and perifollicular inflammation may be 
a possible causative agent. Women are more often 
affected, presenting with diffuse or localized 
dysesthesia and these symptoms may be described 
by patients as pain, pruritus, or burning [4]. It has 
been previously associated with alopecia areata (AA), 
telogen effluvium, lupus erythematosus, 
dermatomyositis, folliculitis decalvans, and lichen 
planus pilaris (LPP) and its variants [2,4,5]. 
Trichodynia is a common symptom in patients with 
hair loss that negatively impacts quality of life [4]. It 
may be refractory to conventional therapies and 
does not yet have a specific therapeutic guideline. 
For these cases, LDN would be a possible alternative 
to be added to the standard therapeutic regimen. 
Regarding alopecias, the use of LDN has already 
been reported in LPP and AA [2,6], with included 
benefits being reduction of symptoms of pruritus, 
clinical evidence of decreased scalp inflammation, 
and inhibition of disease progression [2]. In the 
authors’ experience, the use of LDN has produced a 
remarkable improvement in trichodynia, but as 
opposed to a report by Strazzulla et al. [2], we did not 
observe a change in inflammation and disease 
status. In clinical practice, although without 
consensus, the suggested dose ranges from 1 to 
5mg/day, usually starting at 3mg and increasing  
gradually to 5mg/day. Because many opioid 
receptors are located in the same nuclei that are 
active in sleep regulation, nocturnal use is 
recommended [1,7]. Vivid dreams and insomnia are 
possible side effects, which can be mitigated by 
changing drug administration from bedtime to 
morning [3, 8]. Pregnancy and opioid dependence 
are absolute contraindications. It is important to note 
that LDN can hypersensitize patients to exogenous 
opioids. Thus, physicians should be aware of drug 
interactions in patients taking opioid analgesics [7,8]. 
Nonetheless, LDN has no drug interactions described 
with the drugs commonly used for the treatment of 
alopecias presenting with trichodynia, which include 
systemic corticosteroids, methotrexate, hydroxy-
choloroquine, and cyclosporine [8]. 
 
Conclusion 
Owing to its anti-inflammatory properties, analgesic 
potential, low cost, and few adverse effects 
described, LDN seems to be a complementary option 
in the therapeutic arsenal for alopecias presenting 
with trichodynia [2-4]. Although patients report 
improvement of symptoms, it is not known how 
much the anti-inflammatory action aids in the course 
of the underlying disease. Further studies with larger 
number of patients are needed to standardize 
dosing, better understand its mechanism of action, 
and evaluate its potential therapeutic indications. 
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